Clinical trial · Interventional
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
PILOT STUDY OF THE CORRELATION BETWEEN THE FINDINGS OF ATYPICAL/MALIGNANT CELLS IN SPUTUM AND FLUORESCENCE BRONCHOSCOPY IN PATIENTS AT RISK FOR LUNG CANCER OF THE LIFE IMAGING SYSTEM AND WHITE LIGHT BRONCHOSCOPY
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer. PURPOSE: A pilot study to evaluate fluorescent light bronchoscopy plus conventional bronchoscopy as a tool for screening and detecting lung cancer in persons with completely resected head and neck cancer or successfully treated early-stage lung cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bronchoscopic and lung imaging studies | Procedure | — | UNRESOLVED |
| bronchoscopy | Procedure | — | UNRESOLVED |
| comparison of screening methods | Procedure | — | UNRESOLVED |
| cytology specimen collection procedure | Other | — | UNRESOLVED |
| endoscopic biopsy | Procedure | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| sputum cytology | Other | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * The following diagnoses are eligible: * Known or suspected bronchogenic carcinoma scheduled for bronchoscopy as part of standard diagnostic or staging work-up * Completely resected stage I/II non-small cell lung cancer with no evidence of metastasis * Stage III non-small cell lung cancer with no evidence of disease for at least 2 years following treatment * Small cell lung cancer with no evidence of disease for at least 2 years following treatment * Completely resected head and neck cancer with no evidence of metastasis * Ability to produce sputum samples required PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Hematopoietic: * WBC 2,000-20,000 * Platelets at least 50,000 Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No uncontrolled hypertension (i.e., systolic pressure greater than 200 mm Hg or diastolic pressure greater than 120 mm Hg) * No unstable angina Other: * No bleeding disorder * No allergic reaction to topical lidocaine * No pregnant women PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * At least 18 months since ionizing radiotherapy to the chest Surgery * See Disease Characteristics Other * At least 1 month since yttrium-aluminum-garnet (YAG) laser therapy to the lung * At least 3 months since fluorescent photosensitizing drugs (e.g., Photofrin)
References
Publications (0)
Data not yet available